Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 276Neoplasms 255Prostatic Neoplasms 216Colorectal Neoplasms 196Lung Neoplasms 153Multiple Myeloma 148Neoplasm Metastasis 135Ovarian Neoplasms 126Leukemia, Myeloid, Acute 123Pancreatic Neoplasms 116Melanoma 102Squamous Cell Carcinoma of Head and Neck 97Recurrence 85Endometrial Neoplasms 82Carcinoma, Renal Cell 80Glioblastoma 78Lymphoma, Non-Hodgkin 77Stomach Neoplasms 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Carcinoma, Hepatocellular 72Glioma 65Brain Neoplasms 65Uterine Cervical Neoplasms 63Sarcoma 63Head and Neck Neoplasms 63Triple Negative Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 58Urinary Bladder Neoplasms 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mastocytosis × 30 days × Clear all
NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡